| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2024/06/14 | 13 : 15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 09 : 51 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 09 : 49 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 09 : 45 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 09 : 40 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 09 : 39 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 09 : 39 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 09 : 37 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 09 : 30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 06 : 18 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 06 : 16 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 06 : 14 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 06 : 12 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 06 : 10 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 06 : 08 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 06 : 06 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 06 : 04 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 06 : 02 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/12 | 06 : 01 | Edgar (US Regulatory) | Form POSASR - Post-effective Amendment to an automatic shelf registration statement | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/11 | 22 : 25 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/11 | 22 : 18 | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/11 | 22 : 15 | Edgar (US Regulatory) | Form SC TO-T/A - Tender offer statement by Third Party: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/03 | 20 : 00 | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/06/03 | 20 : 00 | Business Wire | Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/05/28 | 19 : 08 | Edgar (US Regulatory) | Form SC TO-T/A - Tender offer statement by Third Party: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/05/22 | 22 : 06 | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/05/22 | 20 : 01 | Edgar (US Regulatory) | Form SC TO-T/A - Tender offer statement by Third Party: [Amend] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/05/13 | 19 : 32 | Edgar (US Regulatory) | Form SC 14D9 - Solicitation, recommendation statements | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/05/13 | 19 : 31 | Edgar (US Regulatory) | Form SC TO-T - Tender offer statement by Third Party | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |
| 2024/05/10 | 20 : 27 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:DCPH | Deciphera Pharmaceuticals Inc |